When taken over a prolonged period of at least one year, these medications do much more than help control blood sugar or weight. GLP-1 Drugs and Heart Health in High-Risk Patients The analysis focused on adults already at elevated risk of cardiovascular disease, including people with type 2 diabetes, obesity, or existing heart conditions
While this was no doubt an exciting breakthrough for type-2 diabetes treatments, what has catapulted them front and center is their ability to aid in weight loss
Strengthening Biocons GLP-1 Portfolio Siddharth Mittal, CEO and MD of Biocon Limited, highlighted the strategic importance of this launch, noting that it reinforces the companys focus on peptide-based therapies and leverages Biocons vertically integrated, end-to-end manufacturing capabilities
Glutathione Induced Immune-Stimulatory Activity by Promoting M1-Like Macrophages Polarization via Potential ROS Scavenging Capacity
when dosing stops, baseline appetite regulation returns to pre-treatment levels
A request has been submitted to create a multicounty litigation (MCL), which is a group lawsuit representing people who developed NAION
